Niki BioSolutions,

Niki BioSolutions, Interest Coverage

Interest Coverage Ratio of Niki BioSolutions, (NIKI) as of Oct 17, 2026.

Interest Coverage

-

Last updated:

Interest Coverage Ratio of Niki BioSolutions, is 2026 - . Interest Coverage Ratio of Niki BioSolutions, was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Niki BioSolutions, Stock analysis

What does Niki BioSolutions, do? Niki BioSolutions, Inc. is a clinical-stage biopharmaceutical company based in Princeton, US, focused on developing therapeutic products for oncology and infectious diseases. The company operates through a pipeline including SACT-1 (Phase 1 for neuroblastoma), ALS-4 (Phase 1 for bacterial infections), and preclinical candidates like SACT-COV19 and ALS-1 targeting coronavirus and MRSA. It was formerly Aptorum Group Limited, rebranding in July 2026 following its listing on 17 July 2026. Niki BioSolutions, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Niki BioSolutions, stock

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Niki BioSolutions, since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Niki BioSolutions, with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Niki BioSolutions,

All Key Metrics — Niki BioSolutions,